Krka has been granted a positive opinion recommending granting a pan-European marketing authorization for its generic version of Janssen’s Zytiga (abiraterone). The European Medicines Agency’s Committee for Medicinal Products for Human Use endorsed the treatment for metastatic prostate cancer in the form of 500mg film-coated tablets.
“Studies have demonstrated the satisfactory quality of Abiraterone Krka, and its bioequivalence to the reference product Zytiga,” the CHMP stated....




